Successful alectinib treatment for a mechanically ventilated patient with &lt;i&gt;ALK&lt;/i&gt;-positive non-small cell lung cancer

Watanabe, Yasutaka; Koyama, Nobuyuki; Iwai, Yasuhiro; Kawamura, Rumi; Miwa, Chihiro; Nagai, Yoshinori; Hagiwara, Koichi; Koyama, Shinichiro

doi:10.4993/acrt.24.47

Cited by 5 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Review of agents found 36 (31%) with guidance for alternative routes of administration readily available in tertiary resources or commercial liquid formulations, 38 (33%) with off‐label manufacturer information or case reports describing manipulation of solid dosage formulations, and 42 (36%) with no data or insight limited to pharmacokinetic studies. Findings are detailed in Table 3 10‐196 . Unique administration instructions (ie, with or without foo...…”

Section: Resultsmentioning

confidence: 99%

Medication use process and assessment of extemporaneous compounding and alternative routes of administration of oral oncology drugs: Guidance for clinical and oncology pharmacists

Cohen

Lee

Markham

et al. 2022

J Am Coll Clin Pharm

View full text Add to dashboard Cite

Cancer treatment is evolving. Oral formulations offer potentially more convenient, effective alternatives to conventional chemotherapy for many cancers. An appealing aspect of oral antineoplastic agents is their relative ease of administration; unfortunately, patients may have difficulty swallowing the tablets or capsules. This shift towards oral administration and the accompanying issues around oral medication adherence highlights the need to assess the safety and feasibility of delivery methods for patients unable to swallow solid dosage forms. A new medication‐use process (MUP) was created to facilitate extemporaneous compounding of oral oncology drugs (OOD). Systematic review consisting of tertiary resources, drug manufacturers, and primary literature was performed to identify information related to extemporaneous compounding or alternative routes of administration for a predetermined list of OODs. A single‐center retrospective review was conducted of patients receiving liquid formulations of OODs to characterize institutional experience. Overall, 116 OODs were reviewed. The majority of OODs had information describing extemporaneous compounding or alternative routes of administration (31% with commercial liquid formulations available or information in tertiary resources; 33% with off‐label manufacturer information or case reports) while 36% had no data. The MUP included three compounding workflows to account for available solid dosage formulations (tablet, hard capsule, gelatin capsule) and creation of an electronic health record order template. Retrospective review identified 41 patients who received compounded liquid formulations of 14 OODs for 13 indications. Liquid OODs were used for a median of 3‐5 days. None of the 41 patients experienced discernable safety or overt effectiveness concerns readily attributed to use of liquid OODs. Implementation of a novel MUP and systematic review of OODs aids the pharmacist in standardizing institutional practice and mitigates risks associated with extemporaneous liquid formulations of OODs facilitating medication delivery of new agents to patients unable to swallow solid dosage forms.

show abstract

Section: Resultsmentioning

confidence: 99%

Medication use process and assessment of extemporaneous compounding and alternative routes of administration of oral oncology drugs: Guidance for clinical and oncology pharmacists

Cohen

Lee

Markham

et al. 2022

J Am Coll Clin Pharm

View full text Add to dashboard Cite

show abstract

“…Two additional case reports demonstrated continued response to therapy without adverse effects. 17,18 The reports used a water-based and non-specified recipe, respectively. Both preparations were administered via NG tube, with one report utilizing a PEG tube as well.…”

Section: Discussionmentioning

confidence: 99%

Enteral tube administration of oral chemotherapy drugs

Spencer

Menard

Labedz

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

Objective Patients receiving oral chemotherapies face treatment interruptions if they require placement of an enteral tube for nutrition, potentially leading to adverse outcomes in cancer treatment. Enteral tube medication administration can provide a suitable alternative. The purpose of this review is to compile available data that describe enteral tube administration of oral chemotherapy agents. Data sources: A systematic evaluation of all Food and Drug Administration-approved oral chemotherapy agents through 31 July 2019 was conducted. Information on crushing or opening of the tablet or capsule, enteral tube administration, and extemporaneous formulations was compiled from the prescribing information, tertiary resources, and primary literature. Drug manufacturers were contacted for additional information. Data summary: A total of 87 oral chemotherapy agents were evaluated. Of the 87 drugs, 33 agents (37.9%) had information regarding enteral tube administration with only four drugs with nasogastric or gastric tube administration instructions in their prescribing information. The strength of evidence varied from non-peer reviewed data to complete evaluations of efficacy and safety. The majority of chemotherapies (62%) had no available data on enteral tube administration. Conclusions The results of this review suggest that there is limited data surrounding enteral tube administration of most oral chemotherapies, demonstrating the need for more studies to be conducted to provide more guidance to healthcare providers when administration via an enteral tube is needed in their patients.

show abstract

Crizotinib

2017

Reactions Weekly

View full text Add to dashboard Cite

Successful alectinib treatment for a mechanically ventilated patient with <i>ALK</i>-positive non-small cell lung cancer

Cited by 5 publications

References 14 publications

Medication use process and assessment of extemporaneous compounding and alternative routes of administration of oral oncology drugs: Guidance for clinical and oncology pharmacists

Medication use process and assessment of extemporaneous compounding and alternative routes of administration of oral oncology drugs: Guidance for clinical and oncology pharmacists

Enteral tube administration of oral chemotherapy drugs

Crizotinib

Contact Info

Product

Resources

About